Malaria Research and Treatment / 2013 / Article / Tab 3

Clinical Study

Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes

Table 3

Incidence of biological markers of adverse events in patients on AS/AQ or AL during 28 days of followup.

Laboratory parameterAS/AQAL
% %

 Bilirubin > 1 mg/dL20/6829.418/6926.1
 Alanine transaminase > 37 mg/dL01/6801.500
 Creatinine > 11 mg/dL001/6901.4
 Anaemia (Hb < 9.5 g/dL)23/6833.821/6930.4
 Leucopenia (WBC < 5000/ L)12/6817.613/6918.8
 Lymphopenia (lymph < 4.0)10/6814.710/6914.5
 Neutropenia (neutro < 1.5)02/6802.909/6913.0
 Platelets (platelets < )02/6802.903/6904.3

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.